Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

HCM

HUTCHMED (China) Limited ADR

Apr 18 • 04:00PM ET

16.36

Dollar change -0.09
Percentage change -0.55	%

Healthcare • Drug Manufacturers - Specialty & Generic • Hong Kong • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	28.47	EPS (ttm)	0.57	Insider Own	2.30%	Shs Outstand	174.25M	Perf Week	-9.56%
Market Cap	2.85B	Forward P/E	197.49	EPS next Y	0.08	Insider Trans	0.00%	Shs Float	170.25M	Perf Month	-4.27%
Income	99.32M	PEG	-	EPS next Q	-	Inst Own	7.10%	Short Float	0.29%	Perf Quarter	7.07%
Sales	844.58M	P/S	3.38	EPS this Y	-201.31%	Inst Trans	-18.35%	Short Ratio	3.73	Perf Half Y	-10.41%
Book/sh	4.19	P/B	3.90	EPS next Y	113.63%	ROA	8.60%	Short Interest	0.50M	Perf Year	-5.49%
Cash/sh	5.09	P/C	3.22	EPS next 5Y	-	ROE	14.81%	52W Range	10.68 - 20.73	Perf YTD	-9.66%
Dividend Est.	-	P/FCF	14.95	EPS past 5Y	-	ROI	12.71%	52W High	-21.08%	Beta	0.81
Dividend TTM	-	Quick Ratio	2.60	Sales past 5Y	35.89%	Gross Margin	54.03%	52W Low	53.18%	ATR (14)	0.75
Dividend Ex-Date	-	Current Ratio	2.72	EPS Y/Y TTM	127.85%	Oper. Margin	1.94%	RSI (14)	46.38	Volatility	3.25% 3.09%
Employees	1988	Debt/Eq	0.12	Sales Y/Y TTM	94.29%	Profit Margin	11.76%	Recom	1.31	Target Price	26.16
Option/Short	Yes / Yes	LT Debt/Eq	0.07	EPS Q/Q	-79.15%	Payout	0.00%	Rel Volume	1.40	Prev Close	16.45
Sales Surprise	-4.21%	EPS Surprise	27.27%	Sales Q/Q	53.61%	Earnings	Feb 28 AMC	Avg Volume	134.38K	Price	16.36
SMA20	-4.04%	SMA50	2.88%	SMA200	2.37%	Trades		Volume	187,961	Change	-0.55%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-24-23	Upgrade	Deutsche Bank	Hold → Buy
May-04-22	Downgrade	Deutsche Bank	Buy → Hold
Sep-22-21	Downgrade	Goldman	Buy → Neutral	$46
Aug-03-21	Initiated	Jefferies	Buy	$52
Oct-02-20	Initiated	Deutsche Bank	Buy	$40
Mar-13-20	Initiated	Cantor Fitzgerald	Overweight
Feb-20-20	Initiated	Goldman	Buy
Nov-19-19	Initiated	CLSA	Buy
Oct-23-19	Reiterated	BofA/Merrill	Buy	$35 → $29
Jul-05-19	Initiated	Macquarie	Outperform

Apr-05-24 04:30AM	HUTCHMED Highlights Data to be Presented at AACR Congress 2024 (GlobeNewswire)
Apr-02-24 12:30AM	HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status (GlobeNewswire)
Mar-27-24 08:00PM	HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC (GlobeNewswire)
08:00PM	HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naive or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC (GlobeNewswire)
Mar-21-24 08:00PM	HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China (GlobeNewswire)
06:30AM	Loading…
Feb-28-24 06:30AM	HUTCHMED Reports 2023 Full Year Results and Provides Business Updates (GlobeNewswire)
Feb-06-24 07:00PM	HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session (GlobeNewswire) +11.84%
Feb-02-24 03:30AM	HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership (GlobeNewswire)
Feb-01-24 03:30AM	HUTCHMED to Announce 2023 Final Results (GlobeNewswire)
Jan-29-24 11:53PM	HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer (GlobeNewswire)
Jan-10-24 07:00PM	HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status (GlobeNewswire)
Dec-12-23 11:30PM	HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Terms (GlobeNewswire)
07:00PM	HUTCHMED Announces that it has Completed Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China (GlobeNewswire)
Nov-30-23 07:00PM	HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses (GlobeNewswire)
Nov-10-23 08:35AM	Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing (GlobeNewswire) +5.14%
07:11PM	Loading…
Nov-08-23 07:11PM	HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA (fruquintinib) for Previously Treated Metastatic Colorectal Cancer (GlobeNewswire)
Nov-01-23 08:35AM	International companies to host live webcasts at Deutsche Banks Depositary Receipts (GlobeNewswire)
Oct-31-23 08:35PM	International companies to host live webcasts at Deutsche Banks Depositary Receipts Virtual Investor Conference on November 8th and 9th, 2023 (GlobeNewswire)
Oct-16-23 04:30AM	HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2023 (GlobeNewswire)
Oct-10-23 12:08PM	Decoding HUTCHMED (China) Ltd (HCM)'s Performance Potential: A Deep Dive into Key Metrics (GuruFocus.com)
Oct-05-23 05:17PM	Ray Dalio on Potential US-China War and Rise of China (Insider Monkey)
Sep-29-23 04:30AM	HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan (GlobeNewswire)
Sep-25-23 12:20PM	Is HUTCHMED (China) Ltd (HCM) Set to Underperform? Analyzing the Factors Limiting Growth (GuruFocus.com) +6.44%
Sep-18-23 12:14PM	Decoding HUTCHMED (China) Ltd (HCM)'s Performance Potential: A Deep Dive into Key Metrics (GuruFocus.com) +8.63%
Sep-12-23 04:30AM	HUTCHMED Highlights Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer (GlobeNewswire)
Sep-11-23 08:00PM	HUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China (GlobeNewswire) +6.63%
12:14PM	Decoding HUTCHMED (China) Ltd (HCM)'s Performance Potential: A Deep Dive into Key Metrics (GuruFocus.com)
Aug-28-23 08:00PM	HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer (GlobeNewswire)
Aug-20-23 08:00PM	HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China (GlobeNewswire)
Aug-03-23 01:07AM	HUTCHMED (China) First Half 2023 Earnings: EPS: US$0.20 (vs US$0.19 loss in 1H 2022) (Simply Wall St.) +11.57%
07:41AM	Loading…
Jul-31-23 07:41AM	HUTCHMED Reports 2023 Interim Results and Provides Business Updates (GlobeNewswire)
Jul-19-23 08:00PM	HUTCHMED Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study (GlobeNewswire)
Jul-13-23 04:30AM	HUTCHMED Announces Changes to Board of Directors and Technical Committee (GlobeNewswire)
Jul-09-23 08:00PM	HUTCHMED Initiates Phase I Study of its novel SHP2 inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China (GlobeNewswire)
Jun-26-23 04:30AM	HUTCHMED to Announce 2023 Half-Year Financial Results (GlobeNewswire)
Jun-15-23 08:30PM	HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The Lancet (GlobeNewswire) +8.20%
10:30AM	Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency (GlobeNewswire)
Jun-09-23 05:30AM	HUTCHMED Highlights Presentations for Hematological Malignancy Programs at the 2023 EHA and ICML Meetings (GlobeNewswire)
May-25-23 07:00PM	Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review (GlobeNewswire)
06:00PM	HUTCHMED Highlights Presentations at the 2023 ASCO Annual Meeting (GlobeNewswire)
May-18-23 08:35AM	Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing (GlobeNewswire) -5.63%
May-15-23 08:15AM	International companies to host live webcasts at Deutsche Banks Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023 (GlobeNewswire) +5.79%
May-12-23 04:30AM	HUTCHMED Announces Board of Directors and Board Committee Membership (GlobeNewswire)
May-11-23 05:00AM	International companies to host live webcasts at Deutsche Banks Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023 (GlobeNewswire)
May-10-23 04:30AM	HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committees (GlobeNewswire)
May-09-23 01:36PM	International companies to host live webcasts at Deutsche Banks Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023 (GlobeNewswire) -9.34%
Apr-17-23 08:00PM	HUTCHMED Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric Cancer (GlobeNewswire) -5.25%
Apr-11-23 08:00PM	HUTCHMED Highlights Presentations at American Association for Cancer Research Annual Meeting 2023 (GlobeNewswire) +5.87%
04:30AM	Intended Retirement of Independent Non-executive Director (GlobeNewswire)
Apr-04-23 05:30AM	HUTCHMED Initiates Registration Phase Enrollments of HMPL-453 for IHCC and Savolitinib for Gastric Cancer following NMPA Consultations (GlobeNewswire) +6.26%
Mar-30-23 08:00PM	HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer (GlobeNewswire)
Mar-14-23 09:30AM	HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China (GlobeNewswire) +7.26%
Mar-12-23 08:07PM	HUTCHMED Confirms No Assets Held at Silicon Valley Bank (GlobeNewswire)
Feb-28-23 03:30AM	HUTCHMED Reports 2022 Full Year Results and Provides Business Updates (GlobeNewswire) +5.35%
Feb-27-23 05:00AM	HUTCHMED Completes Patient Enrollment of Phase II Registration Trial of Amdizalisib in Follicular Lymphoma in China (GlobeNewswire)
Jan-31-23 03:30AM	HUTCHMED to Announce 2022 Final Results (GlobeNewswire)
Jan-23-23 08:00AM	HUTCHMED Out Licenses Fruquintinib To Takeda Outside China (Benzinga) +5.95%
03:00AM	HUTCHMED Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China (GlobeNewswire)
Jan-18-23 09:30AM	HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in China (GlobeNewswire)
Jan-03-23 03:30AM	HUTCHMED Completes Patient Enrollment of ESLIM-01, a Phase III Trial of Sovleplenib in Primary Immune Thrombocytopenia in China (GlobeNewswire) +10.83%
Dec-19-22 05:00AM	HUTCHMED Initiates Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Colorectal Cancer (GlobeNewswire)
Dec-16-22 06:27AM	Prenetics Acquires ACT Genomics, Creating a Leader in Comprehensive Cancer Genetics and Precision Oncology (GlobeNewswire)
Nov-18-22 08:35AM	Deutsche Bank ADR Investor Conference: Presentations Now Available for On-Demand Viewing (GlobeNewswire)
Nov-14-22 07:00PM	HUTCHMED Announces Strategy to Focus on Late-Stage Pipeline Regulatory Approvals (GlobeNewswire) +10.91%
07:40AM	Hutchmed-Lilly Partnered Gastric Cancer Drug Shows Mixed Results In Phase 3 Study (Benzinga)
Nov-13-22 07:00PM	HUTCHMED Announces Positive Topline Result in Fruquintinib Phase III FRUTIGA Study in Second-Line Gastric Cancer in China (GlobeNewswire)
Nov-09-22 06:30PM	International companies to host live webcasts at Deutsche Banks Depositary Receipts Virtual Investor Conference on November 16th and 17th, 2022 (GlobeNewswire) -6.80%
Oct-27-22 07:30AM	HUTCHMED Initiates a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China (GlobeNewswire)
Oct-10-22 04:30AM	HUTCHMED Initiates a Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China (GlobeNewswire)
Sep-08-22 01:33PM	HUTCHMED Cancer Med Cuts Death Risk By 34% In Metastatic Colorectal Cancer (Benzinga) +5.63%
Sep-07-22 06:30PM	HUTCHMED Highlights Phase III FRESCO-2 MRCT Data Summary of Fruquintinib in Refractory Metastatic Colorectal Cancer from the Upcoming ESMO 2022 Presentation (GlobeNewswire)
Aug-23-22 04:30AM	HUTCHMED Highlights Fruquintinib MRCT FRESCO-2 Data to be Presented at the Upcoming ESMO Congress 2022 (GlobeNewswire)
Aug-09-22 04:30AM	Inmagene and HUTCHMED Announce First Participant in Global Phase I Trial of IMG-004 (GlobeNewswire)
Aug-08-22 06:02AM	HUTCHMED and AstraZeneca Announce that TAGRISSO® Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and/or Amplification in SAVANNAH Phase II Trial (GlobeNewswire)
Aug-07-22 08:00PM	HUTCHMED Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer (GlobeNewswire)
Aug-01-22 07:00AM	HUTCHMED Reports 2022 Interim Results and Provides Business Updates (GlobeNewswire) -7.65%
02:00AM	HUTCHMED Initiates a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China (GlobeNewswire)
Jul-15-22 04:30AM	HUTCHMED Initiates Phase I Trial of Anti-CD47 Monoclonal Antibody HMPL-A83 in Patients with Advanced Malignant Neoplasms in China (GlobeNewswire)
Jul-14-22 12:00PM	Hutchison China MediTech (HCM) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Jul-13-22 12:28PM	HUTCHMED Highlights SAVANNAH Trial Data Of Savolitinib Combo In Lung Cancer Setting (Benzinga)
Jul-12-22 08:00PM	HUTCHMED Highlights First Presentation of Results of the SAVANNAH Global Phase II Trial of Savolitinib plus TAGRISSO® at the 2022 WCLC Annual Meeting (GlobeNewswire) -10.67%
Jul-06-22 12:40AM	Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-007 (GlobeNewswire)
Jun-27-22 04:30AM	HUTCHMED to Announce 2022 Half-Year Financial Results (GlobeNewswire)
Jun-01-22 04:33AM	HUTCHMED Announces TAZVERIK® Approved to be Used in Hainan Pilot Zone in China (GlobeNewswire) -11.22%
May-16-22 07:00AM	Appointment of NonExecutive Director (GlobeNewswire)
May-15-22 07:00PM	Inmagene Receives FDA IND Clearance for a Third Generation BTK Inhibitor Targeting Immunological Diseases (PR Newswire)
May-12-22 09:54AM	Deutsche Banks Depositary Receipts Virtual Investor Conference presentations now available for on-demand viewing (GlobeNewswire)
May-08-22 08:30PM	International companies to host live webcasts at Deutsche Banks Depositary Receipts Virtual Investor Conference on May 10th and 11th, 2022 (GlobeNewswire)
May-05-22 08:58AM	International companies to host live webcasts at Deutsche Banks Depositary Receipts Virtual Investor Conference on May 10th and 11th, 2022 (GlobeNewswire) -9.53%
May-02-22 06:00AM	HUTCHMED Receives Complete Response Letter from the U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors (GlobeNewswire) -18.95%
Mar-31-22 12:00AM	Update on Status under Holding Foreign Companies Accountable Act (GlobeNewswire)
Mar-11-22 04:00AM	Update on Status under Holding Foreign Companies Accountable Act (GlobeNewswire) -7.52%
Mar-06-22 11:30PM	HUTCHMED Receives a US$15 million Milestone from AstraZeneca for Initiating Start-up Activities for a Global Phase III Study of ORPATHYS® in Lung Cancer (GlobeNewswire)
Mar-03-22 07:30AM	HUTCHMED announces retirement of CEO and appointment of new CEO (GlobeNewswire) -6.95%
07:00AM	HUTCHMED Reports 2021 Full Year Results and Provides Business Updates (GlobeNewswire)
Mar-01-22 03:30AM	HUTCHMED Receives Approval to Commercialize ELUNATE® in Macau (GlobeNewswire)
Feb-10-22 03:06AM	Genetron Health Announces Companion Diagnostic Collaboration Agreement with HUTCHMEDs ORPATHYS® for NSCLC (GlobeNewswire)
Feb-07-22 03:30AM	HUTCHMED to Announce 2021 Final Results (GlobeNewswire)
Feb-04-22 04:30AM	HUTCHMED Initiates Phase Ib/II Study of HMPL-453 in Combination with Chemotherapy or Toripalimab for Advanced Solid Tumors in China (GlobeNewswire)
Jan-19-22 07:00PM	HUTCHMED Initiates a Phase I Trial of HMPL-653 in Patients with Advanced Malignant Solid Tumors and TGCT in China (GlobeNewswire)

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

HCM

HUTCHMED (China) Limited ADR

Upgrade your FINVIZ experience